Interestingly, valsartan, an antagonist of angiotensin type 1 receptor (AT1R), significantly attenuates HHcy-induced cardiac hypertrophy in normotension, indicating an involvement of AT1R activation in HHcy's pathogenic effects [34]. Here, AGTR1 is linked to cardiac hypertrophy.